Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | WNT3A | P56704 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765956 | 0.95 | CASP1 (0.41) | CASP1MAPTELANEKCNH2MAPK11 | |
| SCHEMBL30765555 | 0.91 | CASP1 (0.42) | CASP1ELANEKCNH2WNT3A | |
| SCHEMBL30765831 | 0.85 | CASP1 (0.40) | CASP1ELANEKCNH2WNT3A | |
| SCHEMBL30765696 | 0.85 | CASP1 (0.39) | CASP1MAPTELANEKCNH2MAPK11 | |
| SCHEMBL30765738 | 0.83 | CASP1 (0.42) | CASP1ELANEKCNH2WNT3A | |
| SCHEMBL30765978 | 0.81 | ELANE (0.41) | CASP1ELANETP53 | |
| SCHEMBL30765546 | 0.80 | CASP1 (0.40) | CASP1ELANEKCNH2WNT3A | |
| SCHEMBL30765813 | 0.79 | ELANE (0.42) | CASP1ELANEWNT3A | |
| SCHEMBL30765568 | 0.78 | ELANE (0.43) | ELANE | |
| SCHEMBL30765803 | 0.73 | CASP1 (0.47) | CASP1MAPTELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |